HighLife
HighLife Medical develops a transcatheter mitral-valve replacement system designed to treat patients with severe mitral regurgitation without open-heart surgery.
€80MFinancing round
LeadLoading investors…
Activity from announced rounds
HighLife Medical develops a transcatheter mitral-valve replacement system designed to treat patients with severe mitral regurgitation without open-heart surgery.
Amyl Therapeutics is developing immunotherapies that target amyloid aggregates linked to neurodegenerative disease.
Pitching Mérieux Equity Partners? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room